so popular

Bayou City comes close to topping Census Bureau's list for greatest population boom in the country

Houston added more than a million people in the last decade. Photo by Scott Halleran/Getty Images

The Lone Star State is proving quite popular, at least according to the U.S. Census Bureau. As reported by numbers released on March 26, Texas is home to cities with the fastest-growing large metro area in the nation and the biggest numeric gain of residents.

Those would be Austin and Dallas-Fort Worth, respectively. And we'll delve into their numbers in a minute, because first it's time to talk about Houston.

H-Town actually nipped at DFW's heels in terms of the numeric population gain from 2010 to 2019. In that time, the Houston area picked up 1,145,654 residents, the second highest total among U.S. metros. That's around the number of people who live in the Buffalo, New York, metro area.

Houston stills holds the No. 5 position on the list of the largest U.S. metro areas. The bureau put its 2019 population at 7,066,141, up 19.4 percent from 2010.

Austin, meanwhile, saw its population shoot up 29.8 percent between 2010 and 2019, landing at 2,227,083 as of July 1, 2019. Put another way, the Austin area added 510,760 residents during the one-decade span.

From 2018 to 2019 alone, the Austin area's population rose 2.8 percent, the Census Bureau says. Numerically, the one-year increase was 61,586 (taking into account births, deaths, new arrivals to the area, and people moving away). That works out to 169 people per day.

Helping drive the Austin area's population spike from 2010 to 2019 were two of the country's fastest-growing counties. Hays County ranked as the second-fastest growing county in the U.S. (46.5 percent) in the past decade, the Census Bureau says, with Williamson County at No. 9 (39.8 percent).

In terms of numeric growth, Travis County ranked 10th in the country from 2010 to 2019 with the addition of 249,510 residents, according to the Census Bureau.

While Austin was the fastest-growing major metro area from 2010 to 2019, Dallas-Fort Worth topped the Census Bureau list for the biggest numeric gain. During that period, DFW welcomed 1,206,599 residents. To put that into perspective, that's about the same number of people who live in the entire Salt Lake City metro area.

On July 1, 2019, DFW's population stood at 7,573,136, up 19 percent from 2010. It remains the country's fourth largest metro, behind New York City, Los Angeles, and Chicago.

Although the San Antonio metro area didn't make the top 10 for percentage or numeric growth from 2010 to 2019, two of the region's counties appeared among the 10 fastest-growing counties:

  • Ranked at No. 4, Comal County's population jumped 43.9 percent.
  • Ranked at No. 5, Kendall County's population rose 42.1 percent.

In the previous decade, the San Antonio area's population climbed 19.1 percent, winding up at 2,550,960 in 2019, the Census Bureau says. Over the 10-year period, the region added 408,440 residents.

------

This article originally ran on CultureMap.

Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News